New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
10:52 EDTGSK, AMRNFish oil market may be bigger challenge than patents for Amarin, Forbes says
Scientific publications, doctors' commentary, and prescription trends all hint that the U.S. market for prescription fish oil may be shifting dramatically, which could be a bigger problem for Amarin (AMRN) than patent protection for its Vascepa drug, according to Forbes. Use of GlaxoSmithKline's (GSK)Lovaza, an alternative treatment, has declined, the report added. Reference Link
News For AMRN;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
18:37 EDTGSKViiV, Desano enter strategic manufacturing agreement for Tivicay
Subscribe for More Information
June 26, 2015
10:38 EDTGSKCourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
June 25, 2015
14:01 EDTGSKGlaxoSmithKline initiated with a Buy at HSBC
Price target GBP 17.
June 24, 2015
13:37 EDTGSKGSK says CDC committee votedfor meningococcal group B vaccines
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
June 23, 2015
07:25 EDTGSKPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use